ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its first quarter 2022 financial results on May 5, 2022, after market close. An executive conference call will commence at 5:00 p.m. ET to discuss these results and address inquiries. Participants can join via phone or through a webcast available on the company's website. ChemoCentryx specializes in developing therapies for inflammatory diseases, including TAVNEOS (avacopan), an approved treatment for severe active ANCA-associated vasculitis. The company is also advancing late-stage candidates for hidradenitis suppurativa and C3 glomerulopathy.

Positive

• ChemoCentryx is developing TAVNEOS, approved for ANCA-associated vasculitis, and is in late-stage trials for hidradenitis suppurativa and C3 glomerulopathy.

Negative

• None.

SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on May 5, 2022 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 6597218. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS^® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information about the Company visit www.chemocentryx.com.

TAVNEOS^® is a registered trademark of ChemoCentryx, Inc. For more information, please see the Full Prescribing Information and Medication Guide, available at TAVNEOS.com.

Contacts
Investors:
Bill Slattery, Jr.
Vice President, Investor Relations
& Corporate Communications
650.210.2970
bslattery@chemocentryx.com

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

FAQ

What are the upcoming financial results for ChemoCentryx scheduled for release?

ChemoCentryx will release its first quarter 2022 financial results after market close on May 5, 2022.

When will the ChemoCentryx conference call occur?

The conference call to discuss the financial results will begin at 5:00 p.m. ET on May 5, 2022.

How can I access the ChemoCentryx conference call?

You can access the conference call by dialing (877) 303-8028 for domestic callers or (760) 536-5167 for international callers. A live audio webcast will also be available on their website.

What is TAVNEOS and its significance for ChemoCentryx?

TAVNEOS (avacopan) is ChemoCentryx's approved treatment for severe active ANCA-associated vasculitis and is significant for its role in expanding the company's market presence.

What other conditions is ChemoCentryx developing treatments for?

ChemoCentryx is also developing treatments for severe hidradenitis suppurativa and C3 glomerulopathy.